Arvinas
Price & Volume
Stats
See more52W Range | $5.90-$29.61 |
Market Cap | $694.5M |
Shares Short | 7M |
Financials
See moreRevenue (12 Mos) | $372.8M |
Revenue Growth (YoY) | -70.7% |
Gross Profit (12 Mos) | $392M |
Diluted EPS | -$1.01 |
News
See moreYahoo Finance • 6 days ago
Arvinas Presents Late Breaking, Positive Phase 1 Clinical Data for ARV-102, a PROTAC LRRK2 Degrader, at the 2025 International Congress of Parkinson’s Disease and Movement Disorders®
Yahoo Finance • 10 days ago
Arvinas to Present Clinical Data for ARV-102, a PROTAC LRRK2 Degrader, at the 2025 International Congress of Parkinson’s Disease and Movement Disorders®
Yahoo Finance • 16 days ago
Amazon upgraded, Adobe downgraded: Wall Street’s top analyst calls
Yahoo Finance • 17 days ago
Amazon upgraded, Adobe downgraded: Wall Street's top analyst calls
About
CEO | Dr. John G. Houston Ph.D. |
CFO | Mr. Andrew R. Saik |
Address | 5 Science Park, New Haven, CT, United States, 06511 |
Sector | Healthcare |
Industry | Biotechnology |
Full-Time Employees | 430 |
